An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Trial Profile

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2013

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Oct 2008 Results were reported at the annual meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals.
    • 24 Oct 2008 Primary endpoint 'Fibromyalgia Impact Questionnaire' has been met.
    • 24 Oct 2008 Secondary endpoint 'Medical Outcome Study Short Form 36' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top